Clinical Trial

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

Study acronym: Monoclonal
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-12.
Status change: Not Yet Recruiting → Recruiting 2025-08-03
Trial Details
NCT Number NCT07021794
Lead Sponsor Nancy Klimas
Collaborators: Florida Department of Health
Conditions Post-COVID / Long-COVID
Enrollment 100 participants
Start Date 2025-06-16
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-05